Literature DB >> 13678735

Clinical disease course during the last year in ovarian cancer.

Vivian E von Gruenigen1, Heidi E Frasure, Anne Marie Reidy, Karen M Gil.   

Abstract

OBJECTIVE(S): The objective was to determine whether there were changes in the pattern and nature of hospitalizations during the last year that could be used in the assessment of whether chemotherapy should be continued.
METHODS: Retrospective data were collected from patients who died from ovarian cancer between 1/2000 and 12/2001. Charts from four hospitals were reviewed to abstract chemotherapy, reason for hospitalization, and the incidence of three significant clinical events (bowel obstruction, pleural effusion requiring thoracentesis, and abdominal ascites requiring paracentesis). Data were analyzed in 3-month intervals.
RESULTS: Sixty-two patient charts were reviewed. Quarterly admissions increased linearly over the year (7, 18, 27, and 47, P < 0.0001). Hospitalizations for ascites, bowel obstruction, and pleural effusion began increasing around 6 months preceding death. Twenty-two patients did not receive chemotherapy during the last 3 months. Of the 40 patients receiving chemotherapy in the last 3 months, over half were not hospitalized during the period 4-6 months before death, and a further 20% were hospitalized for nonsignificant clinical events. Approximately one-quarter of the patients, however, continued to receive chemotherapy following hospitalization for a significant clinical event. CONCLUSION(S): There were significant changes in the pattern and nature of hospitalization during the last 6 months that included hospitalizations for bowel obstruction, pleural effusion, or ascites. The occurrence of these events suggests that further chemotherapy should be realistically evaluated with the patient, which may reduce the number of patients who receive chemotherapy during their last few months of life.

Entities:  

Mesh:

Year:  2003        PMID: 13678735     DOI: 10.1016/s0090-8258(03)00418-9

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Promoting timely goals of care conversations between gynecologic cancer patients at high-risk of death and their providers.

Authors:  Brittany A Davidson; Allison M Puechl; Catherine H Watson; Stephanie Lim; Luke Gatta; Karen Monuszko; Kerry Drury; Emma S Ryan; Shelley Rice; Tracy Truong; Jessica Ma; Steve Power; Weston Jordan; Kelli Kurtovic; Laura J Havrilesky
Journal:  Gynecol Oncol       Date:  2021-12-16       Impact factor: 5.482

2.  Caring for a patient with malignant pleural effusion.

Authors:  Jeanne Held-Warmkessel; Linda Schiech
Journal:  Nursing       Date:  2008-11

3.  A pilot study of long-acting octreotide for symptomatic malignant ascites.

Authors:  Aminah Jatoi; Jorge J Nieva; Rui Qin; Charles L Loprinzi; Edward J Wos; Paul J Novotny; Dennis F Moore; Rex B Mowat; Naftali Bechar; Eduardo R Pajon; Lynn C Hartmann
Journal:  Oncology       Date:  2012-05-10       Impact factor: 2.935

4.  A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.

Authors:  Daniel S Green; Ana T Nunes; Virginia David-Ocampo; Irene B Ekwede; Nicole D Houston; Steven L Highfill; Hanh Khuu; David F Stroncek; Seth M Steinberg; Kathryn C Zoon; Christina M Annunziata
Journal:  J Transl Med       Date:  2018-07-16       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.